Cocrystal Pharma, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for COCP, updated each market day.
COCP AI Sentiment
AI sees no strong directional signal for Cocrystal Pharma, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Cocrystal Pharma, Inc. Common Stock
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Sector
Exchange
Market Cap
$19,437,920
Cap Tier
Employees
10
Headquarters
BOTHELL, WA
Listed Since
April 1, 2008
Website
COCP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
COCP Volatility
Cocrystal Pharma, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
